

I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Epilepsy Research Program

Idea Development Award

Announcement Type: Initial

Funding Opportunity Number: W81XWH-22-ERP-IDA

**Assistance Listing Number: 12.420 Military Medical
Research and Development**

SUBMISSION AND REVIEW DATES AND TIMES

- **Pre-Application Submission Deadline:** 5:00 p.m. Eastern time (ET), May 19, 2022
- **Application Submission Deadline:** 11:59 p.m. ET, June 23, 2022
- **End of Application Verification Period:** 5:00 p.m. ET, June 28, 2022
- **Peer Review:** August 2022
- **Programmatic Review:** October 2022

This program announcement must be read in conjunction with the General Application Instructions, version 701. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”

TABLE OF CONTENTS

| | |
|--|-----------|
| I. OVERVIEW OF THE FUNDING OPPORTUNITY..... | 1 |
| II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY..... | 3 |
| II.A. Program Description..... | 3 |
| II.A.1. FY22 ERP Focus Areas..... | 3 |
| II.A.2. Award History | 4 |
| II.B. Award Information | 4 |
| II.C. Eligibility Information..... | 10 |
| II.C.1. Eligible Applicants | 10 |
| II.C.2. Cost Sharing..... | 11 |
| II.C.3. Other | 12 |
| II.D. Application and Submission Information..... | 12 |
| II.D.1. eBRAP and Grants.gov..... | 12 |
| II.D.2. Content and Form of the Application Submission | 13 |
| II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM) | 28 |
| II.D.4. Submission Dates and Times..... | 28 |
| II.D.5. Funding Restrictions..... | 29 |
| II.D.6. Other Submission Requirements | 31 |
| II.E. Application Review Information | 31 |
| II.E.1. Criteria | 31 |
| II.E.2. Application Review and Selection Process..... | 34 |
| II.E.3. Integrity and Performance Information..... | 35 |
| II.E.4. Anticipated Announcement and Federal Award Dates..... | 35 |
| II.F. Federal Award Administration Information | 35 |
| II.F.1. Federal Award Notices..... | 35 |
| II.F.2. Administrative and National Policy Requirements | 36 |
| II.F.3. Reporting..... | 37 |
| II.G. Federal Awarding Agency Contacts..... | 37 |
| II.G.1. eBRAP Help Desk..... | 37 |
| II.G.2. Grants.gov Contact Center | 38 |
| II.H. Other Information..... | 38 |
| II.H.1. Program Announcement and General Application Instructions Versions..... | 38 |
| II.H.2. Administrative Actions..... | 38 |
| II.H.3. Application Submission Checklist..... | 41 |
| APPENDIX 1: ACRONYM LIST | 43 |
| APPENDIX 2: SAMPLE CONSENT LANGUAGE | 45 |

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2022 (FY22) Epilepsy Research Program (ERP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). *The ERP was initiated in 2015 to support longitudinal epidemiological research to better understand the incidence of post-traumatic epilepsy (PTE) following a traumatic brain injury (TBI) and to improve patient care and outcomes.* The FY22 ERP challenges the research community to (1) investigate topics related to epileptogenesis for the identification of mechanisms by which brain injury produces epilepsy, (2) study the prevention of PTE and concomitant comorbidities, and (3) develop innovative research tools or biomarkers to better detect, diagnose, or predict the development of PTE. Appropriations for the ERP from FY15 through FY21 totaled \$61.5 million (M). The FY22 appropriation is \$12.0M.

The ERP encourages collaboration among PTE researchers and urges the scientific community to utilize equitable partnerships with people living with PTE to maximize the translational and impact potential of proposed research. Applications from investigators within the military Services and applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged.

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

II.A.1. FY22 ERP Focus Areas

Applications to the FY22 ERP Idea Development Award (IDA) should address at least one of the Focus Areas listed below. Applications may address more than one Focus Area. An application that proposes research outside of these FY22 ERP Focus Areas is also acceptable, as long as the applicant provides a strong justification as to why the topic is critical to advance understanding of PTE and addresses the ERP mission.

- **Markers and Mechanisms:** Identifying biomarkers or mechanisms of PTE, which may include the following:
 - Predictive biomarkers of epileptogenesis (acute and chronic)
 - Research into the prevention of epilepsy and/or seizures

- **Epidemiology:** Epidemiological characterization of PTE following TBI, which may include the following:
 - Understanding and improving the quality of life of individuals with PTE, their families, and/or their care partners
 - Predictors of the development of epilepsy
 - Outcomes, including latency to and prevention of epilepsy, comorbidities, and mortality
- **Longitudinal Studies:** Studies of the evolution of PTE, which may include the following:
 - Understanding and improving the quality of life of individuals with PTE, their families, and/or their care partners
 - Treatment and healthcare outcomes research, including quality of care
 - Natural history of PTE and prognosis
 - Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
- **Innovative Research:** Tools intended to better inform or improve upon PTE research and care, which may include the following:
 - Strategies that will improve seizure detection, characterization, visualization, or diagnosis
 - Development of new models or better characterization of existing etiologically relevant models for PTE

II.A.2. Award History

The ERP Idea Development Award mechanism was first offered in FY15. Since then, 219 IDA applications have been received, and 51 have been recommended for funding.

II.B. Award Information

The intent of the FY22 ERP IDA is to solicit novel, innovative research that has the potential to increase our understanding of post-traumatic epilepsy to improve quality of life, especially in Service Members, Veterans, and/or their care partners. The work should innovatively challenge existing research paradigms or exhibit high levels of creativity. ***The FY22 ERP IDA offers two levels of funding dependent upon the level of experience of the Principal Investigator (PI):***

- **Funding Level I - Pathway to Independence Option** – open to postdoctoral fellows or investigators within 3 years of their first independent faculty position (*or equivalent*)
- **Funding Level II - Innovative New Direction Option** – open to independent investigators at or above the level of assistant professor (*or equivalent*)

Funding levels are contingent upon meeting the eligibility requirements described in [Section II.C, Eligibility Information](#).

Important aspects of this award mechanism include:

- **Impact:** Applications should articulate the short- and long-term impact of the proposed research on the PTE research field, patient care, and those living with PTE. Projects should address one or more of the [FY22 ERP Focus Areas](#) or provide a strong justification as to why the alternative topic is critical to advance understanding of PTE and addresses the ERP mission. Applicants are encouraged to consult with individuals living with PTE during the development and execution of the proposed research project, to ensure research outcomes maximize translational and impact potential.
- **Innovation:** Applications should propose innovative ideas or approaches to address questions relevant to PTE. Innovative research may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities.
- **Relevance to Military Health:** Projects must be relevant to military Service Members, their families, and Veterans with PTE. Collaboration with military and VA researchers and clinicians is encouraged.
- **Experience in PTE Research:** The PI on the application can be from any field or discipline; however, it is **CRITICAL** that the application demonstrate the study team's experience in PTE research, including expertise in the fields of **BOTH** TBI and epilepsy.

Preliminary data are encouraged but NOT required. *Although preliminary data are not required, evidence demonstrating the ability of the applicant to execute the chosen model of TBI within their laboratory or the laboratory of a collaborator is required.*

Clinical trials are not allowed under this funding opportunity. Permitted research includes preclinical studies in animal models, observational research with human subjects, or research involving human anatomical substances or data, as well as ancillary studies associated with an existing clinical trial. When appropriate, applicants are encouraged to leverage ongoing cohort studies, such as [Transforming Research and Clinical Knowledge in TBI \(TRACK-TBI\)](#), [TBI-Model Systems](#), and [Long-Term Impact of Military-Relevant Brain Injury Consortium Chronic Effects of Neurotrauma Consortium \(LIMBIC-CENC\)](#).

Employing community collaborations to optimize research impact is encouraged but NOT required. Research funded by the FY22 ERP should be responsive to the needs of people with PTE, their families, and/or their care partners. Research teams are therefore encouraged to establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of the proposed research.

Collaborative research approaches such as community-based participatory research (CBPR), participatory action research (PAR), and integrated knowledge transition (IKT), create partnerships between scientific researchers and community members to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific

researchers and community members *collaborate and contribute equitably* on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. *Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of community members within the research team.* Research results are jointly interpreted, disseminated, fed back to affected communities, and may be translated into interventions or policy. These methods are critically important for community-level interventions and can also have important impacts on translational research and prototype development to identify and augment the potential impact of a research program on people living with PTE, their families, and/or their care partners.

Collaborative research approaches are characterized by the equitable collaboration between community members and researchers. These collaborative relationships are often established through integrating community members into research teams as co-researchers, advisors, and/or consultants. Some examples for implementing collaborative research approaches include:

- **Lived Experience Consultation:** The research team includes at least one project advisor with lived PTE experience who will provide advice and consultation throughout the planning and implementation of the research project. Lived Experience Consultants may include individuals with PTE, their family members, or their care partners.
- **Partnership with a community-based organization:** The research team establishes partnerships with at least one community-based organization that provides advice and consultation throughout the planning and implementation of the research project. Community-based organizations may include advocacy groups, service providers, policy makers, or other formal organizational stakeholders.
- **Community Advisory Board:** A community advisory board is composed of multiple community stakeholders and can take many forms, from a board of Lived Experience Consultants to a coalition of community-based organizations or any combination thereof. As with Lived Experience Consultants and organizational partners, the community advisory board provides advice and consultation throughout planning and implementation of the research project.

Additional information on collaborative research approaches can be found here:

- Wallerstein N and Duran B. 2010. [Community-based participatory research contributions to intervention research: The intersection of science and practice to improve health equity.](#) *American Journal of Public Health* 100(S1):S40-S46. doi: 10.2105/AJPH.2009.184036.
- Jull J, Giles A, and Graham ID. 2017. [Community-based participatory research and integrated knowledge translation: advancing the co-creation of knowledge.](#) *Implementation Science* 12(1):150. doi: 10.1186/s13012-017-0696-3.

Experimental design should maximize rigor and reproducibility. All projects should adhere to accepted standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. Core standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research.

Nature 2012, 490:187-191 (<https://www.nature.com/articles/nature11556>). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Applicants should consult the ARRIVE 2.0 (*Animal Research: Reporting In Vivo Experiments*) guidelines to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE 2.0 guidelines can be found at <https://arriveguidelines.org/arrive-guidelines>.

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the Department of Defense (DOD) during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated direct costs budgeted for the entire period of performance for a Funding Level I FY22 ERP Idea Development Award will not exceed **\$300,000**. Refer to [Section II.D.5, Funding Restrictions](#), for detailed funding information.

The anticipated direct costs budgeted for the entire period of performance for a Funding Level II FY22 ERP Idea Development Award will not exceed **\$550,000**. Refer to [Section II.D.5, Funding Restrictions](#), for detailed funding information.

Awards will be made no later than September 30, 2023. For additional information refer to [Section II.F.1, Federal Award Notices](#).

The CDMRP expects to allot approximately \$1.44M to fund approximately three Funding Level I Idea Development Award applications and \$2.64M to fund approximately three Funding Level II Idea Development Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY22 funding opportunity will be funded with FY22 funds, which will expire for use on September 30, 2028.

Research Involving Animals: All research funded by the FY22 ERP Idea Development Award involving new and ongoing research with animals must be reviewed and approved by the

USAMRDC Office of Research Protections (ORP) Animal Care and Use Review Office (ACURO), in addition to the local Institutional Animal Care and Use Committee (IACUC) of record. IACUC approval at the time of submission is *not* required. ***Allow at least 3 to 4 months for ACURO regulatory review and approval processes for animal studies.*** Refer to the General Application Instructions, Appendix 1, for additional information.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC ORP, Human Research Protection Office (HRPO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is *not* required. Allow up to 3 months to complete the HRPO regulatory review and approval process following submission of ***all required and complete*** documents to the HRPO. Refer to the General Application Instructions, Appendix 1, and the Human Research Protections Office Resources and Overview document available on the electronic Biomedical Research Application Portal (eBRAP) “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) for additional information.

If the proposed research involves more than one institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.

Clinical trials are not allowed under this funding opportunity. As stated in [Section II.H.2.c, Withdrawal](#), applications including a clinical trial as any part of the application may be administratively withdrawn. ***A clinical trial is defined*** as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Clinical research is defined as: (1) Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual. Patient-oriented research includes: (a) mechanisms of human disease, (b) therapeutic interventions, (c) clinical trials, and (d) development of new technologies. (2) Epidemiologic and behavioral studies. (3) Outcomes research and health services research. ***Note:*** Studies that meet the requirements for IRB Exemption 4 are not considered CDMRP-defined clinical research. IRB Exemption 4 refers to research involving the collection or study of existing de-identified specimens or data, if these sources are publicly available.

Use of DOD or VA Resources: If the proposed research involves access to active-duty military or Veteran patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to [Section II.D.2.b.ii, Full Application Submission](#)

[Components](#), for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

Federal Interagency Traumatic Brain Injury Research (FITBIR) Data Sharing: The DOD requires that awardees make TBI research data generated by this award mechanism available to the research community through the FITBIR Informatics System. The FITBIR Informatics System is a free resource designed to accelerate research progress by allowing the storage, re-analysis, integration, and rigorous comparison of multiple datasets. Currently, FITBIR-eligible research includes all studies generating prospectively collected human TBI subject data (e.g., clinical, demographic, phenotypic, imaging, and genomic).

Data reporting to FITBIR is an opportunity for investigators to facilitate their own research and to collaborate with others engaged in similar research. While there is no direct charge to users of the FITBIR Informatics System, a project estimation tool (<https://fitbir.nih.gov/jsp/contribute/fitbir-costs.jsp>) is available to help estimate costs and manpower needs that may be associated with data submission. FITBIR guidance and policies, as well as the considerable advantages of FITBIR participation to the researcher, are detailed at <http://fitbir.nih.gov/>.

In order to share data with FITBIR, three elements must be included in the proposed research:

- Updated informed consent language that includes FITBIR data sharing. Sample consent language is included in [Appendix 2](#).
- Global Unique Identifier (GUID): FITBIR encourages collaboration between laboratories, as well as interconnectivity with other informatics platforms. Such community-wide sharing requires common data definitions and standards. FITBIR allows for de-identification and storage of data (medical imaging clinical assessment, environmental and behavioral history, etc.) of various types (text, numeric, image, time series, etc.). Use of FITBIR's GUID system facilitates repeated and multi-user access to data without the need to personally identify data sources. In order to generate a GUID for a subject, the following personally identifiable information (PII) ***must be collected in the proposed research:***
 - Complete legal given (first) name of subject at birth
 - Complete legal additional name of subject at birth (if subject has a middle name)
 - Complete legal family (last) name of subject at birth
 - Day of birth
 - Month of birth
 - Year of birth
 - Name of city/municipality in which subject was born
 - Country of birth

Note that this PII is never sent to the FITBIR system. PII cannot be extracted from the GUID. Information on GUID compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations can be found at <https://fitbir.nih.gov/content/global-unique-identifier>.

- **Common Data Elements (CDEs):** Research data elements must be reported using the National Institute of Neurological Disorders and Stroke (NINDS) TBI CDEs or entered into the FITBIR data dictionary as new, unique data elements (UDEs). For the most current version of the NINDS TBI CDEs, go to <http://www.commondataelements.ninds.nih.gov>. Assistance will be available to help the researchers map their study variables to specific CDEs and ensure the formats of the CDEs collected are compatible with the FITBIR Informatics System. Use of the TBI CDEs is required wherever possible in an effort to create standardized definitions and guidelines about the kinds of data to collect and the data collection methods that should be used in clinical studies of TBI. *Use of UDEs is strongly discouraged and subject to program approval.*

Note: In addition to the TBI CDEs, applicants are also strongly encouraged to consider developing a plan to incorporate the NINDS CDEs for epilepsy found at the link above.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

Government Agencies Within the United States: Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD, and research institutes.

Intramural DOD Organization: A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center. ***Intramural Submission:*** An application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.

The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator and Mentor

Funding Level I – Pathway to Independence Option:

- **Principal Investigator**

- The named PI must be at or above the level of postdoctoral fellow (e.g., research associate, fellow, medical resident, or equivalent), or within 3 years of their first independent faculty position (or equivalent) at the time of the application submission deadline (excluding time spent in residence or on family medical leave). Lapses in research time or appointments as denoted in the biographical sketch should be explained in the application.
- The PI can be from any field or discipline, but must demonstrate suitable experience relevant to the proposed research.

- **Mentor**

- The mentor must hold a position at or above the level of an associate professor (or equivalent).
- The mentor must be a PTE researcher possessing qualifications, background, and experience in **BOTH** TBI and epilepsy as well as a track record for mentoring early-career investigators in the field.

The PI and mentor DO NOT need to be located at the same organization.

Funding Level II – Innovative New Direction Option:

- **Principal Investigator**

- The named PI must be an independent investigator at or above the level of assistant professor (or equivalent) at the time of the application submission deadline.
- Applicants can be from any field or discipline but study teams are expected to demonstrate expertise in both TBI and epilepsy.

Both Funding Levels:

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.

The CDMRP strongly encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at <https://orcid.org/>.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access **.gov** and **.mil** websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

II.D.1. eBRAP and Grants.gov

eBRAP (<https://ebrap.org>) is a secure web-based system that allows PIs to submit their pre-applications, view and verify extramural full applications submitted to Grants.gov (<https://grants.gov>), receive communications from the CDMRP, and submit documentation during award negotiations and throughout the period of performance. eBRAP also allows intramural organizations to submit full applications following pre-application submission.

Grants.gov is a federal system required to be utilized by agencies to receive and process extramural grant applications. Full applications may only be submitted to Grants.gov after submission of a pre-application through eBRAP.

Contact information for the eBRAP Help Desk and the Grants.gov Contact Center can be found in [Section II.G, Federal Awarding Agency Contacts](#).

Extramural Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

Intramural DOD Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

Note: Applications from an intramural DOD organization or from an extramural federal government organization may be submitted to Grants.gov through a research foundation.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both *pre-application* (eBRAP.org) and *full application* (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to [Table 1, Full Application Guidelines](#)).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. **Incorrect selection of extramural or intramural submission type will delay processing.**

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (<https://eBRAP.org/>).

The applicant organization and associated PI (and mentors) identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the applicant must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

Submission of application information includes assignment of primary and secondary research classification codes, which may be found at

<https://ebrap.org/eBRAP/public/Program.htm>. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**

Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that applicants identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the name, organization, and role of all collaborators and key personnel associated with the application, including any PTE Lived Experience Consultants or representatives of community-based organizations involved in the project.

[FY22 ERP Programmatic Panel members](#) should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to [Section II.H.2.c, Withdrawal](#), or contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

Letter of Intent (LOI) (one-page limit): Provide a brief description of the research to be conducted. Include the Focus Area under which the application will be submitted. Research outside of the [FY22 ERP Focus Areas](#) is acceptable, but a justification as to why the alternative topic is critical to advance understanding of PTE and addresses the ERP mission should be included in the LOI.

LOIs are used for program planning purposes only (e.g., reviewer recruitment) and will not be reviewed during either the peer or programmatic review sessions. *An invitation to submit*

a full application is NOT required after LOI submission and applicants should not expect to receive such an invitation in order to proceed to submitting a full application.

- **Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-application to be accepted and processed.

II.D.2.b. Step 2: Full Application Submission Content

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (<https://grants.gov/>) for extramural organizations or through eBRAP (<https://ebrap.org/>) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the **same version** of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (<https://www.grants.gov/web/grants/applicants/apply-for-grants.html>) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

Do not password protect any files of the application package, including the Project Narrative.

Table 1. Full Application Submission Guidelines

| Extramural Submissions | Intramural DOD Submissions |
|---|--|
| Application Package Location | |
| Download application package components for W81XWH-22-ERP-IDA from Grants.gov (https://grants.gov) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the | Download application package components for W81XWH-22-ERP-IDA from eBRAP (https://ebrap.org). |

| Extramural Submissions | Intramural DOD Submissions |
|---|---|
| application package through the applicant organization for review prior to submission. | |
| Full Application Package Components | |
| <p>SF424 Research & Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.</p> | <p>Tab 1 – Summary: Provide a summary of the application information.</p> <p>Tab 2 – Application Contacts: This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</p> |
| <p>Descriptions of each required file can be found under Full Application Submission Components:</p> <ul style="list-style-type: none"> • Attachments • Research & Related Personal Data • Research & Related Senior/Key Person Profile (Expanded) • Research & Related Budget • Project/Performance Site Location(s) Form • Research & Related Subaward Budget Attachment(s) Form | <p>Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</p> <ul style="list-style-type: none"> • Attachments • Key Personnel • Budget • Performance Sites <p>Tab 4 – Application and Budget Data: Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.</p> |
| Application Package Submission | |
| <p>Create a Grants.gov Workspace. Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.</p> <p>Submit a Grants.gov Workspace Package. An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package at least 24-48 hours prior to the close date to allow time to correct any potential technical issues that may disrupt the application submission.</p> <p>Note: If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID <i>prior to</i> the application submission</p> | <p>Submit package components to eBRAP (https://ebrap.org).</p> <p>Tab 5 – Submit/Request Approval Full Application: After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/ Comptroller/Task Area Manager or equivalent Business Official by email. <i>Do not password protect any files of the application package, including the Project Narrative.</i></p> |

| Extramural Submissions | Intramural DOD Submissions |
|---|---|
| deadline. <i>Do not password protect any files of the application package, including the Project Narrative.</i> | |
| <u>Application Verification Period</u> | |
| The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package may be modified <i>with the exception of the Project Narrative and Research & Related Budget Form.</i> | After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/ Task Area Manager or equivalent Business Official and PI will receive email notification of this status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package may be modified <i>with the exception of the Project Narrative and Research & Related Budget Form.</i> Your Resource Manager/ Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline. |
| Further Information | |
| <p>Tracking a Grants.gov Workspace Package. After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission.</p> <p>Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.</p> | Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements. |

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

II.D.2.b.ii. Full Application Submission Components

- **Extramural Applications Only**

SF424 Research & Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications**

Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 megabytes (MB), and the file size for the entire full application package may not exceed 200 MB.

- **Attachment 1: Project Narrative (10-page limit): Upload as “ProjectNarrative.pdf”.** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

Describe the proposed project in detail using the outline below.

- **Background:** Present the ideas and scientific reasoning behind the proposed research project. Clearly demonstrate that there is sufficient scientific evidence to support the proposed stage of research, this may include preliminary and/or published data. Cite relevant literature. Describe previous experience most pertinent to this project.
- **Hypothesis or Objectives:** State the hypothesis (or hypotheses) or objectives to be tested.
- **Specific Aims:** Concisely explain the project’s specific aims. If the proposed research project is part of a larger study, present only tasks that this ERP award would fund.
- **Focus Area:** Describe how the work aligns to one of the [FY22 ERP Focus Areas](#), or if the work does not align to an FY22 ERP Focus Area, explain the critical research area the application will address and its relevance to the ERP mission. An application that proposes research outside of the [FY22 ERP Focus Areas](#) is acceptable, as long as a strong justification is provided as to why the topic is critical to advance understanding of PTE and addresses the ERP mission.
- **Study Design and Feasibility:** Describe the research strategy, methods, and analyses, including appropriate controls, in sufficient detail for evaluation of its appropriateness and feasibility. Describe the statistical plan as appropriate for the proposed research.

Describe how the studies are designed to achieve the project aims. Address potential problem areas and present alternative methods and approaches.

Indicate whether ongoing cohort studies, such as TRACK-TBI, TBI-Model Systems, LIMBIC-CENC, will be leveraged in the study. If applicable, describe the TBI or Epilepsy CDEs to be collected. If the research proposed is epidemiologic in nature, describe how the research will be conducted in accordance with the 2011 International League Against Epilepsy (ILAE) research guidelines for epidemiologic studies and surveillance of epilepsy found at <https://www.ncbi.nlm.nih.gov/pubmed/21899536>.

If applicable, briefly describe the development and use of animal model(s) including a rationale for the choice of animal model, injury method, and endpoints/outcome measures to be used. Full details will be required in the Animal Research Plan ([Attachment 10](#)). ***Demonstrate that the research team has the ability and capacity to execute the chosen model of TBI.***

If human subjects, human anatomical samples or data will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples or data. Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, racial, and ethnic group, and an accompanying rationale for the selection of subjects. If active-duty military, Veteran, or military family member population(s) will be used in the proposed research project, describe the population(s), the appropriateness of the population(s) for the proposed research, and the feasibility of using the population. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population. **Clinical trials are disallowed in this mechanism.**

- **Research Team Composition:** Describe the composition of the research team in enough detail to demonstrate the study team’s experience in PTE research, including expertise in the fields of ***BOTH*** TBI and epilepsy.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e.,

author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Organizational Support (three-page limit per letter): Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.

Funding Level I applications should provide a signed letter from the mentor's department that acknowledges support for the mentor and for their commitment to providing mentorship for the PI's research.

Letters of Collaboration (if applicable) (three-page limit per letter): Provide a signed letter from each collaborating individual or organization that demonstrates that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator's Commander or Commanding Officer at the intramural organization that authorizes the collaborator's involvement.

Funding Level I applications, should provide a letter of collaboration from the mentor listed in the application.

Intellectual Property: Information can be found in the Code of Federal Regulations, Title 2, Part 200.315 (2 CFR 200.315), "Intangible Property."

- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Commercialization Strategy (if applicable):** Describe the commercialization plan. The plan should include intellectual property, market size, financial analysis, strengths and weaknesses, barriers to the market, competitors, and management team. Discuss the significance of this development effort, when it can be anticipated, and the potential commercial use for the technology being developed.

Inclusion Enrollment Plan (only required if clinical research is proposed):

Provide an anticipated enrollment table(s) for the inclusion of women and minorities appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The Public Health Service (PHS) Inclusion Enrollment Report is a three-page fillable PDF form, which can be downloaded from eBRAP at <https://ebrap.org/eBRAP/public/Program.htm>.

Use of DOD Resources (if applicable): Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOD resources or databases.

Use of VA Resources (if applicable): Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.

- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Technical abstracts should be written using the outline below. The technical abstract should provide an appropriate description of the project’s key aspects; clarity and completeness within the space limits of the technical abstract are highly important.

- **Background:** Present the ideas and reasoning behind the proposed project.
- **Hypothesis or Objectives:** State the hypothesis (or hypotheses) or objectives to be tested.
- **Specific Aims:** State the specific aims of the proposed research project.
- **Study Design:** Briefly describe the study design.
- **Innovation:** Briefly describe how the proposed project is innovative.

- **Impact:** Briefly describe the short- or long-term impact of this study on PTE research, patient care, and/or quality of life. Indicate how the proposed research could benefit the military and/or Veteran populations.
- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. **Do not include proprietary or confidential information. Do not duplicate the technical abstract.** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below. Minimize use of acronyms and abbreviations, where possible. The lay abstract is an important component of the application review process because it addresses issues of particular interest to people living with PTE. **Do not duplicate the technical abstract.**

- Describe the objectives and rationale for the proposed research in a manner that will be readily understood by readers without a background in science or medicine.
- Describe the ultimate applicability and impact of the research to people living with PTE.
 - What populations will it help, and how will it help them?
 - What are the potential applications, benefits, and risks?
 - What is the projected time it may take to achieve a person-related outcome?
 - If the research is too basic for immediate clinical applicability, describe the interim outcomes.
 - What are the likely contributions of the proposed research project to advancing PTE research, patient care, and/or quality of life?
- **Attachment 5: Statement of Work (SOW) (three-page limit): Upload as “SOW.pdf”.** The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>). Recommended strategies for assembling the SOW can be found at <https://ebrap.org/eBRAP/public/Program.htm>.

For the FY22 ERP IDA, refer to the “**Suggested SOW Strategy Generic Research**” document for guidance on preparing the SOW and use the blank SOW format titled “Suggested SOW Format”. The SOW must be in PDF format prior to attaching.

The SOW should include a list of major tasks that support the proposed specific aims, followed by a series of subtasks outlined related to the major tasks and milestones within the period of performance. The SOW should describe only the work for which funding is being requested by this application and, as applicable, should also:

- Include the name(s) of the key personnel and contact information for each study site/subaward site. The contributions of the key personnel should be noted for each task.
- Indicate the number (and type, if applicable) of research subjects (animal or human) and/or human anatomical samples projected or required for each task and at each site. Allocate time within the period of performance to obtain local IACUC/IRB and federal ORP approval (3 to 4 months). Refer to the General Application Instructions, Appendix 1, for additional information regarding regulatory requirements.
- For studies with prospective accrual of human subjects, indicate quarterly enrollment targets.
- Identify cell line(s) and commercial or organizational source(s) to be used.
- FITBIR-eligible research should include:
 - FITBIR investigator and study registration within the first 30 days of the award
 - Sharing of draft data collection forms with FITBIR
 - Annual FITBIR data submissions
- **Attachment 6: Innovation Statement (one-page limit): Upload as “Innovation.pdf”.** Describe how the proposed research is innovative and represents more than an incremental advancement in the field. Indicate how the research will have a significant effect on critical questions relevant to PTE. For example, state how the research examines a new paradigm, challenges existing paradigms, or exhibits high levels of creativity by looking at existing problems from new perspectives. Describe how the proposed project studies a new avenue of research for the laboratory.
- **Attachment 7: Impact Statement (one-page limit): Upload as “Impact.pdf”.** This attachment should be written with a broad audience in mind, including readers without a background in science or medicine

Address the impact of the proposed research on one or more of the [FY22 ERP Focus Areas](#) or an alternative topic critical to advance understanding of PTE. Describe the short- and long-term impact of this study on PTE research, patient care, and/or quality of life, including an assessment of the likelihood that a successful outcome of the proposed research project will lead to a practical application in individuals living with PTE. Indicate how the proposed research project is applicable to the healthcare needs and quality of life of injured military Service Members, Veterans, and/or their family members, as well as their care partners.

- **Attachment 8: Data and Research Resource Sharing Plan (two-page limit): Upload as “Sharing.pdf”.** Describe the type of data or research resource to be made publicly available as a result of the proposed work. Describe how data and resources generated during the performance of the project will be shared with the PTE research community.

Include the name of the repository(ies) where scientific data and resources arising from the project will be archived, if applicable. Provide a milestone plan for data/results dissemination including when data and resources will be made available to other users, including dissemination activities with a particular focus on feeding back the data to affected communities and/or research participants.

For applications involving FITBIR-eligible research:

- Identify and describe the planned NINDS TBI CDEs, alignment to FITBIR data elements and forms, and timelines for integrating data to the FITBIR Informatics System.
- For UDEs, if used, provide a justification as to why existing CDEs are not applicable, appropriate, or are incomplete.

For additional guidance regarding sharing of data and research resources, refer to the General Application Instructions, Appendix 2, Section K.

- **Attachment 9: Mentor Statement (one-page limit): Upload as “Mentor.pdf”.** (*Attachment 9 is only applicable and required for applications submitted under Funding Level I.*)
 - Describe the mentor’s background in PTE research, along with their qualifications, and experience in TBI and epilepsy research as it relates to the proposed research. Explain how the mentor will assist the PI throughout the period of performance in developing the skills necessary to be a successful independent researcher including resources available at the mentor’s institution, if different from that of the PI’s. Provide details on the amount and types of interactions between the mentor and the PI. Describe the track record of the mentor for mentoring early-career investigators in TBI and epilepsy research. In addition, the mentor should provide a letter of collaboration describing their involvement in the proposed work as part of the application’s Supporting Documentation ([Attachment 2](#)).
- **Attachment 10: Animal Research Plan (three-page limit): Upload as “AnimalResPlan.pdf”.** (*Attachment 10 is only applicable and required for applications proposing animal studies.*) If the proposed study involves animals, a summary describing the animal research that will be conducted must be included in the application. The Animal Research Plan may not be an exact replica of the protocol(s) submitted to the IACUC. The Animal Research Plan should address the following points to achieve reproducible and rigorous results for each proposed animal study:
 - Briefly describe the research objective(s) of the animal study. Explain how and why the animal species, strain, and model(s) being used can address the scientific objectives and, where appropriate, the study’s relevance to human biology. **Be specific as to why an animal model is necessary to address the study aims, why the specific animal and injury model were chosen over other models, and how they are optimal for addressing the study aims.**

- Summarize the procedures to be conducted. Describe how the study will be controlled.
- Describe the randomization and blinding procedures for the study, and any other measures to be taken to minimize the effects of subjective bias during animal treatment and assessment of results. If randomization and/or blinding will not be utilized, provide justification.
- Provide a sample size estimate for each study arm and the method by which it was derived, including power analysis calculations.
- Describe how data will be handled, including rules for stopping data collection, criteria for inclusion and exclusion of data, how outliers will be defined and handled, statistical methods for data analysis, and identification of the primary endpoint(s).
- **Attachment 11: Collaborative Research Plan: Upload as “Collaboration.pdf”.** (*Attachment 11 is only applicable for applications utilizing a collaborative research approach.*)
 - **Collaborative Research Statement (three-page limit):** For the FY22 ERP, it is encouraged that research teams establish and utilize effective and equitable collaborations and partnerships with community members to maximize the translational and impact potential of proposed research. If a collaborative research approach will be utilized by the applicant, a Collaborative Research Statement should be provided in which the applicant should:
 - Describe the collaborative research approach that will be used (e.g., Lived Experience Consultation, partnership with community-based organization, community advisory board, co-researcher model) including a justification for the approach as well as when the approach will be used within the research project.
 - Indicate the input that will be captured and how this input will be meaningfully integrated and incorporated into the needs assessment, planning, design, execution, analysis, and/or dissemination of the research.
 - Detail the resource allocation and decision making processes to be employed.
 - Describe any training that will be provided to both scientific researchers and community members on collaborative research approaches, decision making, and equitable participation.
 - Describe co-learning and capacity-building activities among all partners.
 - Outline the process measures to assess the effectiveness of the chosen collaborative research approach.
 - **Letters of Community Collaboration, (two-page limit per letter):** Provide a letter signed by each Lived Experience Consultant or community-based partner confirming

- their role and commitment to participate on the research team. If a community-based organization will be engaged, the letter of commitment should be signed by BOTH the organization point of contact leading the engagement along with the organization's leadership endorsing the collaboration. The letter should include the qualifications and background of the Lived Experience Consultant(s), community-based partner, and/or organization point of contact and describe the relevance of those qualifications to the proposed research project.
- **Attachment 12: Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the Required Representations template available on eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.
 - **Attachment 13: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”.** If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DOD Military Facility Budget Format”, available for download on the eBRAP “Funding Opportunities & Forms” web page <https://ebrap.org/eBRAP/public/Program.htm>, including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.

- **Extramural and Intramural Applications**

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681[a] et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

Research & Related Personal Data: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- **PI Biographical Sketch (five-page limit):** Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The

National Institutes of Health (NIH) Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.

- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
 - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
 - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
- Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf”.
 - Include the mentor’s biographical sketch (**Funding Level I applications only**).
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
 - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
 - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
 - Include the mentor’s previous/current/pending support (**Funding Level I applications only**).

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

- **Extramural Applications Only**

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.
- **Intramural DOD Collaborator(s):** Complete the “Suggested Collaborating DOD Military Facility Budget Format” and upload to Grants.gov attachment form as [Attachment 13](#). (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)

The applicant organization must be registered as an entity in SAM (<https://www.sam.gov/SAM/>) and receive confirmation of an “Active” status before submitting an application through Grants.gov. As published in the Federal Register, July 10, 2019, (<https://www.federalregister.gov/documents/2019/07/10/2019-14665/unique-entity-id-standard-for-awards-management>), the UEI for awards management generated through SAM will be used instead of the Data Universal Numbering System (DUNS) number as of April 2022. ***All federal awards including, but not limited to, contracts, grants, and cooperative agreements will use the UEI.*** USAMRDC will transition to use of the UEI beginning with FY22 announcements and utilize the latest SF424, which includes the UEI. The DUNS will no longer be accepted. Applicant organizations will not go to a third-party website to obtain an identifier. During the transition, your SAM registration will automatically be assigned a new UEI displayed in SAM. (For more information, visit the General Services Administration: <https://www.gsa.gov/about-us/organization/federal-acquisition-service/office-of-systems-management/integrated-award-environment-iae/iae-information-kit/unique-entity-identifier-update>.) Current SAM.gov registrants are assigned their UEI and can view it within SAM.gov. ***Authorized Organizational Representatives with existing eBRAP accounts should update their organizational profile to include the UEI prior to submission of the full application to Grant.gov (see Section II.D.4, Submission Dates and Times below).*** Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in [Section I, Overview of the Funding Opportunity](#). Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify

the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. ***If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, ***with the exception of the Project Narrative and Budget Form,*** may be modified.

Intramural DOD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, ***with the exception of the Project Narrative and Budget Form,*** may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

The maximum period of performance is **3** years.

For Funding Level I:

The anticipated direct costs budgeted for the entire period of performance will not exceed **\$300,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the government exceeding **\$300,000** direct costs or using an indirect cost rate exceeding the organization’s negotiated rate.

For Funding Level II:

The anticipated direct costs budgeted for the entire period of performance will not exceed **\$550,000**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. No budget will be approved by the government exceeding **\$550,000** direct costs or using an indirect cost rate exceeding the organization's negotiated rate.

For Both Funding Levels:

All direct and indirect costs of any subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **3** years.

For this award mechanism, direct costs must be requested for:

- **Interim (In-Progress) Review (IPR):** Travel costs for the PI to present project information or disseminate project results at a DOD ERP In-Progress Review meeting during the period of performance. For planning purposes, it should be assumed that the meeting will be held during year 2 of the award in the National Capital Area. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

- Travel in support of multi-institution collaborations associated with the proposed work
- Data and research resource sharing costs
- Costs associated with collaborative research approach (e.g., consultant costs, equitable participation training, capacity-building activities)
- Costs for one investigator to travel to one scientific/technical meeting per year in addition to the IPR meeting described above. The intent of travel costs to these scientific/technical meetings is to present project information or disseminate project results from the FY22 ERP IDA.

Must not be requested for:

- Clinical trial costs

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency's procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.*

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following **scored criteria**, which are listed in *decreasing* order of importance:

- **Research Strategy and Feasibility**
 - How well the ideas and scientific reasoning support the proposed research project and demonstrate sufficient evidence to support moving into the proposed stage of research.
 - How well the hypothesis or objectives, research strategy, methods, and analyses are developed and support successful completion of the project aims.
 - To what extent the proposed research project is feasible as described.
 - How well the applicant acknowledges potential problems and addresses alternative approaches.
 - How well the study is designed to achieve the research objectives, including, if applicable, the development and use of animal model(s) and to what extent the chosen animal, injury method, and endpoints/outcome measures are justified.
 - Whether the statistical plan is appropriate for the proposed research.
 - If applicable, how well the application describes TBI or epilepsy CDEs to be collected and whether those CDEs are appropriate.
 - If applicable, how well the application leverages ongoing cohort studies.
 - If applicable, to what extent the application demonstrates the research team's ability and capacity to execute the chosen model of TBI.
 - If applicable, whether the application includes sufficient evidence to support successful recruitment of and access to human subjects, data, and samples and whether the strategy

for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.

- If applicable, how well the study is designed to achieve reproducible and rigorous results, including controls, sample size estimation, blinding, randomization, and data handling.
- If applicable, how well the application addresses the 2011 ILAE research guidelines for epidemiologic studies and surveillance of epilepsy.

- **Innovation**

- Whether the project is innovative and whether it will lead to a new paradigm, challenge existing paradigms, or exhibits high levels of creativity by looking at existing problems from new perspectives.
- To what extent the proposed research represents more than an incremental advancement and will have a significant effect on critical questions relevant to PTE.
- To what degree the proposed research represents a new avenue of research for the laboratory.

- **Impact**

- To what extent the proposed study addresses one or more of the [FY22 ERP Focus Areas](#) or provides a strong justification as to why the topic is critical to advance understanding of PTE and addresses the ERP mission.
- How likely the short- and long-term impact of this study will make significant contributions on PTE research, patient care, and/or quality of life.
- How likely a successful outcome of the efforts will lead to a practical application in individuals living with PTE.
- To what degree the research addresses questions related to the healthcare needs and quality of life of injured military Service Members, Veterans, and/or their family members, as well as their care partners.
- *If a collaborative research approach will be employed*, how well the input of community members will be captured and to what extent this input will be meaningfully integrated and incorporated into the needs assessment, planning, design, execution, analysis, and/or dissemination of the research.

- **Personnel**

- To what extent the study team's background and experience are appropriate to accomplish the proposed research project.

- How well the composition of the study team demonstrates expertise in **BOTH** TBI and epilepsy.
- To what degree the levels of effort are appropriate to ensure successful conduct of the proposed work.
- **Funding Level I:** How well the mentor's qualifications, background, and experience in PTE relate to the proposed research.
- **Funding Level I:** Whether the amount and types of interactions between the mentor and the PI are appropriate to developing the skills necessary for the PI to be a successful independent researcher.
- ***If a collaborative research approach will be employed,*** to what degree the qualifications and background of the Lived Experience Consultant(s), community-based partner(s), and/or organization point of contact are relevant to the proposed research project.

In addition, the following **unscored criteria** will also contribute to the overall evaluation of the application:

- **Data and Research Resource Sharing Plan**

- Whether project data and research resources will be shared with the PTE research community.
- To what extent the plan for sharing of project data and research resources is appropriate and reasonable. If applicable, whether one or more specific repositories are named where scientific data and resources arising from the project will be archived.
- Whether data and outcome dissemination activities, with particular focus on feeding back the data to affected communities, is described and appropriate.

- **Budget**

- Whether the direct costs exceed the allowable direct costs as published in the program announcement.
- Whether the budget is appropriate for the proposed research.

- **Environment**

- To what extent the scientific environment is appropriate for the proposed research project.
- How well the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements).
- To what extent the quality and level of institutional support are appropriate for the proposed research project.

- **Application Presentation**

- To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the Defense Health Program and FY22 ERP, as evidenced by the following:
 - Adherence to the intent of the award mechanism
 - Relevance to military health
 - Program portfolio composition
 - Relative innovation and impact

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. *The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section II.E.1.b, Programmatic Review](#).* Additional information about the two-tier process used by the CDMRP can be found at <https://cdmrp.army.mil/about/2tierRevProcess>. An information paper describing the funding recommendations and review process for the award mechanisms for the ERP will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panel members or applicants that compromise

the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in [Section I, Overview of the Funding Opportunity](#).

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY22 funds are anticipated to be made no later than September 30, 2023. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from the USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI's organization.

Pre-Award Costs: An institution of higher education, hospital, or non-profit organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds. No commitment on the part of the government should be inferred from discussions with any other individual. **The award document signed by the Grants Officer is the official authorizing document.**

Federal Government Organizations: Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

II.F.1.a. PI Changes and Award Transfers

Unless otherwise restricted, changes in PI or organization will be allowed at the discretion of the USAMRAA Grants Officer, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest [DoD R&D General Terms and Conditions](#); the [USAMRAA General Research Terms and Conditions with Institutions of Higher Education, Hospitals, and Non-Profit Organizations: Addendum to the DoD R&D General Terms and Conditions](#); and the [USAMRAA General Research Terms and Conditions with For-Profit Organizations](#), for further information.

New Requirement: Certification Regarding Disclosure of Funding Sources. The proposing entity must comply with Section 223(a) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021, which requires that the PI, Partnering PIs (if applicable), and all key personnel:

- Certify that the current and pending support provided on the application is current, accurate, and complete;

- Agree to update such disclosure at the request of the agency prior to the award of support and at any subsequent time the agency determines appropriate during the term of the award; and
- Have been made aware of the requirements under Section 223(a)(1) of this Act.

False, fictitious, or fraudulent statements or claims may result in criminal, civil, or administrative penalties (218 USC 1001).

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. *If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.*

Annual progress reports as well as a final progress report will be required.

Annual quad charts as well as a final quad chart will be required.

The Award Terms and Conditions will specify if more frequent reporting is required.

PHS Inclusion Enrollment Reporting Requirement (*only required for clinical research studies*): Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to FAPIIS about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the eBRAP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the eBRAP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 701b. The program announcement numeric version code will match the General Application Instructions version code 701.

II.H.2. Administrative Actions

After receipt of applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the application:

- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Innovation Statement is missing ([Attachment 6](#))

- Impact Statement is missing ([Attachment 7](#))
- Mentor Statement is missing (Funding Level I only) ([Attachment 9](#))

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the application:

- An FY22 ERP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. *A list of the FY22 ERP Programmatic Panel members can be found at <https://cdmrp.army.mil/erp/panels/panels22>.*
- The application fails to conform to this program announcement description.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY22, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (<https://cdmrp.army.mil/about/2tierRevProcess>). Applications that include names of personnel from either of these companies may be administratively withdrawn.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.
- Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.

- A clinical trial is proposed.
- The PI does not meet the eligibility criteria.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

II.H.3. Application Submission Checklist

| Application Components | Action | Completed |
|--|--|-----------|
| SF424 Research & Related Application for Federal Assistance (extramural submissions only) | Complete form as instructed | |
| Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only) | Complete tabs as instructed | |
| Attachments | Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf" | |
| | Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf" | |
| | Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf" | |
| | Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf" | |
| | Statement of Work: Upload as Attachment 5 with file name "SOW.pdf" | |
| | Innovation Statement: Upload as Attachment 6 with file name "Innovation.pdf" | |
| | Impact Statement: Upload as Attachment 7 with file name "Impact.pdf" | |
| | Data and Research Resource Sharing Plan: Upload as Attachment 8 with file name "Sharing.pdf" | |
| | Mentor Statement: Upload as Attachment 9 with file name "Mentor.pdf" if applicable | |
| | Animal Research Plan: Upload as Attachment 10 with file name "AnimalResPlan.pdf" if applicable | |
| | Collaborative Research Plan: Upload as Attachment 11 with file name "Collaboration.pdf" if applicable | |
| | Representations (extramural submissions only): Upload as Attachment 12 with file name "RequiredReps.pdf" | |
| | Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 13 with file name "MFBudget.pdf" if applicable | |
| Research & Related Personal Data | Complete form as instructed | |

| Application Components | Action | Completed |
|--|--|-----------|
| Research & Related Senior/Key Person Profile (Expanded) | Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field | |
| | Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field | |
| | Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field | |
| | Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field | |
| Research & Related Budget (extramural submissions only) | Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field | |
| Budget (intramural submissions only) | Suggested DOD Military Budget Format, including justification | |
| Project/Performance Site Location(s) Form | Complete form as instructed | |
| Research & Related Subaward Budget Attachment(s) Form, if applicable | Complete form as instructed | |

APPENDIX 1: ACRONYM LIST

| | |
|-------------|---|
| ACOS/R&D | Associate Chief of Staff for Research and Development |
| ACURO | Animal Care and Use Review Office |
| CBPR | Community Based Participatory Research |
| CDE | Common Data Elements |
| CDMRP | Congressionally Directed Medical Research Programs |
| CFR | Code of Federal Regulations |
| DOD | Department of Defense |
| DoDGARs | Department of Defense Grant and Agreement Regulations |
| DUNS | Data Universal Numbering System |
| eBRAP | Electronic Biomedical Research Application Portal |
| EC | Ethics Committee |
| ERP | Epilepsy Research Program |
| ET | Eastern Time |
| FAD | Funding Authorization Document |
| FAPIIS | Federal Awardee Performance and Integrity Information System |
| FITBIR | Federal Interagency Traumatic Brain Injury Research |
| FY | Fiscal Year |
| GUID | Global Unique Identifier |
| HRPO | Human Research Protection Office |
| IACUC | Institutional Animal Care and Use Committee |
| IDA | Idea Development Award |
| IKT | Integrated Knowledge Transition |
| ILAE | International League Against Epilepsy |
| IPR | In-Progress Review |
| IRB | Institutional Review Board |
| LIMBIC-CENC | Long-Term Impact of Military Relevant Brain Injury Consortium - Chronic Effects of Neurotrauma Consortium |
| LOI | Letter of Intent |
| M | Million |
| MB | Megabytes |
| MIPR | Military Interdepartmental Purchase Request |
| NIH | National Institutes of Health |

| | |
|-----------|---|
| NINDS | National Institute of Neurological Disorders and Stroke |
| ORCID | Open Researcher and Contributor ID, Inc. |
| ORP | Office of Research Protections |
| PAR | Participatory Action Research |
| PDF | Portable Document Format |
| PHS | Public Health Service |
| PI | Principal Investigator |
| PII | Personally Identifiable Information |
| PTE | Post-Traumatic Epilepsy |
| SAM | System for Award Management |
| SOW | Statement of Work |
| STEM | Science, Technology, Engineering, and/or Mathematics |
| TBI | Traumatic Brain Injury |
| TRACK | Transforming Research and Clinical Knowledge |
| TRACK-TBI | Transforming Research and Clinical Knowledge in TBI |
| UDE | Unique Data Elements |
| UEI | Unique Entity Identifier |
| URL | Uniform Resource Locator |
| USAMRAA | U.S. Army Medical Research Acquisition Activity |
| USAMRDC | U.S. Army Medical Research and Development Command |
| USC | United States Code |
| VA | Department of Veterans Affairs |

APPENDIX 2: SAMPLE CONSENT LANGUAGE

SAMPLE LANGUAGE FOR DISCUSSION OF FITBIR IN INFORMED CONSENT DOCUMENTS

Data from this study may be submitted to the Federal Interagency Traumatic Brain Injury (FITBIR) informatics system. FITBIR is a computer system run by the National Institutes of Health that allows researchers studying traumatic brain injury to collect and share information with each other. With an easier way to share, researchers hope to learn new and important things about traumatic brain injury more quickly than before.

During and after the study, the researchers will send information about you or your child's health and behavior and in some cases, you or your child's genetic information, to FITBIR. However, before they send it to FITBIR, they will remove information such as name, date of birth, and city of birth, and replace that information with a code number. Other researchers nationwide can then file an application to obtain access to your study data for research purposes. Experts who know how to protect health and science information will look at every request carefully to minimize risks to your privacy.

You or your child may not benefit directly from allowing your information to be shared with FITBIR. The information provided to FITBIR might help researchers around the world treat future children and adults with traumatic brain injury so that they have better outcomes. FITBIR will report on its website about the different studies that researchers are conducting using FITBIR data; however, FITBIR will not be able to contact you or your child individually about specific studies.

You may decide now or later that you do not want to share you or your child's information using FITBIR. If so, contact the researchers who conducted this study, and they will tell FITBIR, which can stop sharing the research information. However, FITBIR cannot take back information that was shared before you changed your mind. If you would like more information about FITBIR, this is available on-line at <http://fitbir.nih.gov>

LANGUAGE TO BE USED TO DESCRIBE CERTIFICATES OF CONFIDENTIALITY (3 VERSIONS)

1. Language for new studies that will be consenting subjects for the first time or for ongoing studies that will be re-consenting subjects because they are applying for a COC for the study

To help protect you and/or your child's privacy the investigators of this study [have applied for]/[have obtained] a Certificate of Confidentiality from the National Institutes of Health, part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government.

With this Certificate, we, the investigators, cannot be forced (e.g., by court subpoena) to disclose information that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. Be aware that disclosure of you and/or your child's identity may be found necessary, however, upon request of DHHS for the purpose of audit or evaluation.

You should also understand that a Confidentiality Certificate does not prevent you or a member of your family from **voluntarily** releasing information about your child, yourself, or your involvement in this research. Note however, that if an insurer or employer learns about you and/or your child's participation, and obtains your consent to receive research information, then the investigator may not use the Certificate of Confidentiality to withhold this information. This means that you and your family must also actively protect your own privacy.

We are also asking your consent to provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository, created by the Department of Defense and the National Institutes of Health to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injuries.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by qualified researchers only. Data provided to FITBIR as part of you and/or your child's participation in this research study will be de-identified—i.e., you and/or your child's name will be separated from the data. However, since this institution and others submitting data to FITBIR will retain individually identifying information related to the data they provide, NIH has issued a legislatively authorized "Certificate of Confidentiality" that will help FITBIR and participating institutions avoid being forced to disclose information that may identify you as a FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Finally, you should understand that we, the investigators, are not prevented from taking steps, including reporting to authorities, to prevent serious harm to you, your child, or others. With respect to you and/or your child's participation in FITBIR, we do not plan to make voluntary disclosures except if there were severe threats to the public health or safety.

2. Language for studies that already have a Certificate and will be re-consenting subjects about FITBIR

With your consent, this study will collect and provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository created by the Department of Defense and National Institutes of Health—part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government—to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injury.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by researchers only. Data provided to FITBIR as part of you and/or your child's participation in this research study will be de-identified—i.e., you and/or your child's name will be separated from the data. However, since this institution and others submitting data to FITBIR will retain individually identifying information related to the data they provide, NIH has issued a legislatively authorized "Certificate of Confidentiality" to help FITBIR and participating institutions avoid being forced (e.g., by court subpoena) to disclose information that may identify you as an FITBIR participant in any federal, state, or local civil, criminal, administrative,

legislative, or other proceedings. Be aware that disclosure of you and/or your child's identity may be found necessary, however, upon request of DHHS for the purpose of audit or evaluation.

As you know, we have obtained a Certificate of Confidentiality from NIH that enables us to keep the individually identifiable information that you provide as a research subject private. With this Certificate, we, the investigators cannot be forced to disclose research information collected in this study that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings. This protection will continue to protect you and/or your child's privacy even though we are providing de-identified data to FITBIR.

You should also understand that a Confidentiality Certificate does not prevent you or a member of your family from **voluntarily** releasing information about your child, yourself, or your involvement in this research. Note however, that if an insurer or employer learns about you and/or your child's participation, and obtains your consent to receive research information, then the investigator may not use the Certificate of Confidentiality to withhold this information. This means that you and your family must also actively protect your own privacy.

Finally, as we explained when we told you about this privacy protection before, we, the investigators, are not prevented from taking steps, including reporting to authorities, to prevent serious harm to you and/or your child or others based on information they learn during this study. With respect to you and/or your child's participation in FITBIR, we do not plan to make voluntary disclosures except if there were severe threats to the public health or safety.

3. Language for studies without a Certificate of their own

With your consent, this study will collect and provide research data and related findings to the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system. FITBIR is a biomedical informatics system and data repository created by the Department of Defense and the National Institutes of Health—part of the U.S. Department of Health and Human Services (DHHS), an agency of the U.S. Government—to assist biomedical researchers working to develop a better understanding of traumatic brain injury and/or to develop more effective methods to diagnose, treat and prevent traumatic brain injury.

Data entered into FITBIR will be kept confidential, with FITBIR being designed for access by researchers only. Data provided to FITBIR as part of you or your child's participation in this research study will be de-identified—i.e., you and/or your child's name will be separated from the data. However, since this institution and others submitting data to FITBIR will still retain individually identifying information related to the data provided, the NIH has issued a legislatively authorized "Certificate of Confidentiality" to help FITBIR and participating institutions avoid being forced (e.g., by court subpoena) to disclose information that may identify you as an FITBIR participant in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings.

Finally, you should understand that we, the investigators, are also permitted to make voluntary disclosures with respect to information that is submitted to FITBIR, but do not plan to do so except in the event of severe threats to public health or safety. If, as part of your participation in this research study itself, we learn about serious harm to you, your child or someone else, we would take steps to prevent that harm including notifying appropriate authorities like the police or child welfare.